Live price temporarily unavailable.
Burning Rock Biotech (BNR) is a Health Care company. Latest news and coverage below.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | CN¥208.9M | CN¥381.7M | CN¥429.9M | CN¥507.9M | CN¥563.2M | CN¥537.4M | CN¥515.8M | CN¥539.6M |
| Growth (year over year) | — | +82.7% | +12.6% | +18.1% | +10.9% | −4.6% | −4.0% | +4.6% |
| Gross profit | CN¥135.1M | CN¥273.3M | CN¥313.9M | CN¥364.1M | CN¥380.0M | CN¥363.2M | CN¥362.4M | CN¥402.9M |
| Gross margin | 64.7% | 71.6% | 73.0% | 71.7% | 67.5% | 67.6% | 70.3% | 74.7% |
| Operating income | −CN¥161.4M | −CN¥169.1M | −CN¥412.4M | −CN¥797.1M | −CN¥980.4M | −CN¥669.3M | −CN¥357.6M | −CN¥54.8M |
| Operating margin | −77.3% | −44.3% | −95.9% | −156.9% | −174.1% | −124.5% | −69.3% | −10.2% |
| Net income | −CN¥177.5M | −CN¥169.2M | −CN¥407.2M | −CN¥796.7M | −CN¥971.2M | −CN¥653.7M | −CN¥346.6M | −CN¥55.3M |
| Net margin | −85.0% | −44.3% | −94.7% | −156.9% | −172.4% | −121.6% | −67.2% | −10.3% |
| EPS (diluted) | −CN¥10.38 | −CN¥14.23 | CN¥0.00 | CN¥0.00 | — | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | CN¥93.3M | CN¥94.2M | CN¥1.90B | CN¥1.43B | CN¥905.5M | CN¥615.1M | CN¥519.8M | CN¥478.4M |
| Total assets | — | CN¥847.6M | CN¥2.66B | CN¥2.28B | CN¥1.59B | CN¥1.04B | CN¥885.3M | CN¥820.4M |
| Total liabilities | — | CN¥212.0M | CN¥242.0M | CN¥433.3M | CN¥429.1M | CN¥271.6M | CN¥304.5M | CN¥285.1M |
| Long-term debt | — | CN¥18.3M | CN¥0 | — | — | — | CN¥0 | CN¥1.70M |
| Shareholders' equity | −CN¥603.5M | −CN¥891.5M | CN¥2.42B | CN¥1.85B | CN¥1.16B | CN¥768.4M | CN¥580.8M | CN¥535.3M |
| Cash flow | ||||||||
| Operating cash flow | −CN¥148.8M | −CN¥228.0M | −CN¥73.5M | −CN¥477.9M | −CN¥456.8M | −CN¥255.8M | −CN¥92.3M | −CN¥28.4M |
| Capital expenditure | CN¥23.2M | CN¥43.0M | CN¥60.3M | CN¥204.3M | CN¥62.0M | CN¥8.10M | CN¥5.42M | CN¥5.25M |
| Free cash flow | −CN¥172.0M | −CN¥271.0M | −CN¥133.8M | −CN¥682.2M | −CN¥518.8M | −CN¥263.9M | −CN¥97.7M | −CN¥33.7M |
| Share buybacks | CN¥0 | CN¥3.64M | CN¥0 | CN¥0 | — | — | — | — |
From Burning Rock Biotech's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Chinese Yuan (CNY), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Burning Rock Biotech in our feed yet.